PKN3


Also found in: Wikipedia.

PKN3

A gene on chromosome 9q34.11 that encodes a protein kinase which contributes to invasiveness in prostate cancer; it is not expressed in normal adult tissue.
References in periodicals archive ?
Atu027, which combines our proprietary drug delivery system, AtuPLEX[TM], with AtuRNAi, the Company's proprietary RNAi chemistry, specifically targets PKN3, a protein implicated in cancer growth and metastases.
Atu027 specifically targets PKN3, a molecule involved in cancer growth and metastasis formation.
PKN3 is the target for Silence's lead compound Atu027, which is being developed for the treatment of advanced solid cancers and which is scheduled to enter clinical trials in 2009.
Atu027 specifically targets PKN3, a protein implicated in cancer growth and metastases.
Atu027 incorporates our AtuPLEX[TM] delivery system with AtuRNAi, our proprietary RNAi chemistry and specifically targets PKN3, a protein implicated in cancer growth and metastases.
18 mg siRNA/kg) achieved the same blood plasma siRNA concentration that in preclinical studies had been sufficient to trigger silencing of PKN3 expression.
Atu027 is a liposomal siRNA formulation targeting PKN3 for the treatment of advanced solid cancer.
Atu027 is a proven inhibitor of the expression of PKN3, a molecule that is believed to play an important role in the progression of cancer and metastasis formation in particular.
The granted patent refers to the gene target PKN3, protein kinase N beta, targeted by Silence's lead program Atu027, which is currently in a Phase I clinical study.
of therapeutic agents, thus preventing others from using PKN3 for
The novel kinase target PKN3, discovered by Atugen, is required for malignant prostate cell growth downstream of activated PI 3-kinase.
inhibitor of the expression of PKN3, a gene that is believed to play an